Who are Cozaar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, valsartan/atenolol, continue cozaar, Losartan Tablets, Placebo to Telmisartan, Valsartant treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cozaar — Competitive Intelligence Brief

Cozaar (losartan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ARB (Angiotensin II receptor blocker). Area: Metabolic.

marketed ARB (Angiotensin II receptor blocker) AT1 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Cozaar (losartan) — Merck & Co.. Losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cozaar TARGET	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
valsartan/atenolol	valsartan/atenolol	Novartis	marketed	Angiotensin II receptor blocker / Beta-blocker combination	AT1 receptor (angiotensin II type 1) / Beta-1 adrenergic receptor
continue cozaar	continue cozaar	University of Pittsburgh	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (Angiotensin II Type 1 receptor)
Losartan Tablets	Losartan Tablets	Istituto Auxologico Italiano	marketed	Angiotensin II receptor antagonist (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Placebo to Telmisartan	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Valsartant treatment	Valsartant treatment	University Hospital, Grenoble	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (ARB (Angiotensin II receptor blocker) class)

Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cozaar — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab